Chronic Adverse Events of Anti–PD-1 Treatment Common and Lasting
Source: Clinical Oncology News, August 2021
More than 43% of patients receiving an anti–programmed death (PD)-1 agent for adjuvant treatment of stage III/IV melanoma experience an acute immune-related adverse event (irAE), according to a recent multicenter study.
